Physician profile
Matthew Mcdonnell
NPI 1770785883
$62,007.21
in general payments reported to CMS, 2019-2025
20 companies · $12K in 2025
The $12K reported for 2025 was more than what 89% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,697 · 2020: $5,337 · 2021: $14K · 2022: $7,055 · 2023: $1,593 · 2024: $17K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Food and Beverage: $1,698 · Travel and Lodging: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,090.00 |
| Food and Beverage | $1,697.95 |
| Travel and Lodging | $722.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collagen Matrix, INC | $24,700.00 | 2024-2025 | |
| Stryker Corporation | $9,200.60 | 2019-2021 | |
| Ethicon INC. | $8,213.18 | 2020-2024 | |
| Alphatec Spine, INC | $8,046.55 | 2021-2025 | Other - Miscellaneous |
| Nuvasive, INC. | $5,805.01 | 2019-2023 | Acp, Attrax, Reline |
| Medical Device Business Services, INC. | $4,403.98 | 2019-2025 | Velys |
| Baxter Healthcare | $276.60 | 2019-2025 | Floseal |
| Depuy Synthes Sales INC. | $247.43 | 2020-2025 | Velys |
| Stability Biologics, LLC | $187.15 | 2019-2020 | |
| Royal Biologics, INC. | $154.35 | 2025 | |
| Biocomposites INC | $151.18 | 2025 | Stimulan |
| Mml US, INC. | $132.18 | 2024 | Reactiv8 |
| Medtronic USA, INC. | $117.23 | 2019 | |
| Globus Medical, INC. | $116.49 | 2024 | Xlif |
| Si-Bone, INC. | $92.60 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $64.14 | 2023-2025 | Octrode, Proclaim |
| Providence Medical Technology, INC. | $54.21 | 2025 | |
| Curonix LLC | $27.34 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Pacira Pharmaceuticals Incorporated | $16.99 | 2023 | Iovera, Zilretta, Exparel |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$800,044.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mcdonnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.